Iodine intakes of 100-300 μg/d do not modify thyroid function and have modest anti-inflammatory effects.

Little information is available as to whether doses of iodide similar to those recommended in clinical practice for the prevention of iodine deficiency in pregnant women affect thyroid function. The aim of the present study was to analyse whether doses of iodide can affect thyroid function in adults, and evaluate its effect on plasma markers of oxidative stress, inflammation and acute-phase proteins. A total of thirty healthy volunteers (ten men and twenty women) with normal thyroid function were randomly assigned to three groups (n 10). Each group received a daily dose of 100, 200 or 300 μg of iodide in the form of KI for 6 months. Free tetraiodothyronine (FT4) levels at day 60 of the study were higher in the groups treated with 200 and 300 μg (P = 0·01), and correlated with the increase in urinary iodine (r 0·50, P = 0·007). This correlation lost its significance after adjustment for the baseline FT4. The baseline urinary iodine and FT4 correlated positively with the baseline glutathione peroxidase. On day 60, urinary iodine correlated with C-reactive protein (r 0·461, P = 0·018), and free triiodothyronine correlated with IL-6 (r - 0·429, P = 0·025). On day 60, the changes produced in urinary iodine correlated significantly with the changes produced in α1-antitrypsin (r 0·475, P = 0·014) and ceruloplasmin (r 0·599, P = 0·001). The changes in thyroid-stimulating hormone correlated significantly with the changes in α1-antitrypsin (r - 0·521, P = 0·005) and ceruloplasmin (r - 0·459, P = 0·016). In conclusion, the administration of an iodide supplement between 100 and 300 μg/d did not modify thyroid function in a population with adequate iodine intake. The results also showed a slight anti-inflammatory and antioxidative action of iodide.

Andalucía es salud: 100 citas con la información sobre salud pública

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud

Championnat de Paris [de natation], Pouilley gagnant [du] 100 m libre [Choisy-le-Roi, le 27 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 55187

Hemmi [vainqueur] 100 mètres plat et 200 mètres et de l'équipe relais du 400 mètres [Colombes, 20/7/19 championnat de France d'athlétisme] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 55062

[Edward A.] Teschner [américain], gagnant du 100 m [100 yards d'après le Petit Parisien, championnats de l'armée américaine à Colombes, le 1er juin 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54192

Arrivée du 100 mètres plat [vainqueur Hemmi, Colombes 20/7/19 championnat de France d'athlétisme : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 55052

Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry method in a randomised, crossover study

The recommended treatment for latent tuberculosis (TB) infection in adults is a daily dose of isoniazid (INH) 300 mg for six months. In Brazil, INH was formulated as 100 mg tablets. The treatment duration and the high pill burden compromised patient adherence to the treatment. The Brazilian National Programme for Tuberculosis requested a new 300 mg INH formulation. The aim of our study was to compare the bioavailability of the new INH 300 mg formulation and three 100 mg tablets of the reference formulation. We conducted a randomised, single dose, open label, two-phase crossover bioequivalence study in 28 healthy human volunteers. The 90% confidence interval for the INH maximum concentration of drug observed in plasma and area under the plasma concentration vs. time curve from time zero to the last measurable concentration “time t” was 89.61-115.92 and 94.82-119.44, respectively. The main limitation of our study was that neither adherence nor the safety profile of multiple doses was evaluated. To determine the level of INH in human plasma, we developed and validated a sensitive, simple and rapid high-performance liquid chromatography-tandem mass spectrometry method. Our results showed that the new formulation was bioequivalent to the 100 mg reference product. This finding supports the use of a single 300 mg tablet daily strategy to treat latent TB. This new formulation may increase patients’ adherence to the treatment and quality of life.

Iowa 100% E News, February 2001, Vol.1, no.1

Newsletter for Information Technology Department

Iowa 100% E News, March 2001, Vol.1, no.2

Newsletter for Information Technology Department

Iowa 100% E News, April 2001, Vol.1, no.3

Newsletter for Information Technology Department

Iowa 100% E News, May/June 2001, Vol.1, no.4

Newsletter for Information Technology Department

Iowa 100% E News, July/August 2001, Vol.1, no.5

Newsletter for Information Technology Department

Iowa 100% E News, August/September 2001, Vol.1, no.6

Newsletter for Information Technology Department